GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus

Autor: Johnny, Ludvigsson, David, Krisky, Rosaura, Casas, Tadej, Battelino, Luis, Castaño, James, Greening, Olga, Kordonouri, Timo, Otonkoski, Paolo, Pozzilli, Jean-Jacques, Robert, Henk J, Veeze, Jerry, Palmer, Ulf, Samuelsson, Helena, Elding Larsson, Jan, Åman, Gunilla, Kärdell, Jan, Neiderud Helsingborg, Göran, Lundström, Eva, Albinsson, Annelie, Carlsson, Maria, Nordvall, Hans, Fors, Carl-Göran, Arvidsson, Stig, Edvardson, Ragnar, Hanås, Karin, Larsson, Björn, Rathsman, Henrik, Forsgren, Helena, Desaix, Gun, Forsander, Nils-Östen, Nilsson, Carl-Göran, Åkesson, Päivi, Keskinen, Riitta, Veijola, Timo, Talvitie, Klemens, Raile, Thomas, Kapellen, Walter, Burger, Andreas, Neu, Ilse, Engelsberger, Bettina, Heidtmann, Suzanne, Bechtold, David, Leslie, Francesco, Chiarelli, Alesandro, Cicognani, Giuseppe, Chiumello, Franco, Cerutti, Gian Vincenzo, Zuccotti, Ana, Gomez Gila, Itxaso, Rica, Raquel, Barrio, Maria, Clemente, Maria José, López Garcia, Mercedes, Rodriguez, Isabel, Gonzalez, Juan Pedro, Lopez, Mirentxu, Oyarzabal, H M, Reeser, Roos, Nuboer, Pauline, Stouthart, Natasa, Bratina, Nina, Bratanic, Marc, de Kerdanet, Jacques, Weill, Nicole, Ser, Pascal, Barat, Anne Marie, Bertrand, Jean-Claude, Carel, Rachel, Reynaud, Regis, Coutant, Sabine, Baron

Publikováno v: The New England journal of medicine. 366(5)

The 65-kD isoform of glutamic acid decarboxylase (GAD65) is a major autoantigen in type 1 diabetes. We hypothesized that alum-formulated GAD65 (GAD-alum) can preserve beta-cell function in patients with recent-onset type 1 diabetes.We studied 334 pat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a576e430b0435bf3bd36fb2c21207ef6
https://pubmed.ncbi.nlm.nih.gov/22296077